While differential modulation of APP processing and Aβ transcytosis by PICALM has been reported, significant effects of PICALM modulation of tau pathology progression have also been evidenced in Alzheimer’s disease models. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.